It is well-known that resistance blood vessels play an important role in maintaining the blood pressure and regulating tissue blood flow.1-3) Therefore, an elevated blood pressure in patients with hypertension is frequently managed by decreasing the peripheral vascular resistance in combination with reducing the cardiac output and/or decreasing the blood volume.2,3) Hypertension requires life-long treatment, and it is a major risk factor for various, serious diseases, such as stroke, heart failure, and renal dysfunction.2,3) It is therefore of importance to understand various therapeutic compounds from the viewpoint of their vasodilatory activity in consideration of efficacy and persistency. Such information contributes to an improvement in the appropriateness and effectiveness of hypertension treatment.As for the mechanism accounting for vasodilation, many investigators demonstrated that a cGMP-related process is largely involved in arteriolar smooth muscle relaxation. [4][5][6] That is, following an increase in the intracellular cGMP concentration, protein kinase G is stimulated, and, subsequently, the Ca 2ϩ pump function is activated. This causes the promotion of intracellular Ca 2ϩ efflux, and the resultant decrease in the intracellular Ca 2ϩ concentration leads to arteriolar smooth muscle relaxation. In addition, it is widely known that the arteriolar vascular endothelium plays an important role in vascular tension control by releasing relaxing and contracting factors to promote muscle relaxation and contraction, respectively. 7,8) Compared to this detailed knowledge of the mechanism underlying vasodilation, the differences in the vasodilatory efficacies of various compounds and in their time-dependent profiles are not fully understood.To clarify the basic aspects of the vasodilatory efficacy and persistency of various therapeutic compounds, we investigated the vasodilatory activities of model vasodilators in an isolated perfused mesenteric artery bed of rats. Nitric oxide (NO), acetylcholine (ACh), and sodium nitroprusside (SNP) were selected as model vasodilators due to their well-known pharmacological characteristics. 6,7,9,10) In addition, they involve a common process to exert vasodilatory activity. NO acts as an endothelium-derived relaxing factor, 6,11) stimulating soluble guanylate cyclase to promote cGMP production from GTP. ACh interacts with muscarinic acetylcholine receptors on the endothelium, and, subsequently, it stimulates the endothelial nitric oxide synthase to generate NO, resulting in an increase in the cGMP concentration. 7,9) SNP, known as an NO donor compound, diffuses into the arteriolar smooth muscle cells.2) SNP decomposes there to release NO, causing an increased cGMP concentration and vasodilation. Considering the common process of vasodilation, we characterized their vasodilation profiles in a model-dependent manner to clarify the mechanism accounting for the difference in their vasodilatory efficacies.
MATERIALS AND METHODS
MaterialsA nitric oxide/nitrogen gas mixture (1 : 9) a...